What is the current End-Stage Kidney Disease market size?

The End-Stage Kidney Disease market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the End-Stage Kidney Disease market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing prevalence.

What are the key drivers of the End-Stage Kidney Disease market?

Key drivers include rising diabetes and hypertension cases, and growing demand for dialysis services.

What are the major challenges facing the End-Stage Kidney Disease market?

Challenges include high treatment costs, limited access to healthcare, and shortage of donor kidneys.

Which regions are the leaders in the End-Stage Kidney Disease market?

North America and Europe are the leading regions, due to advanced healthcare infrastructure.

Who are the top companies in the End-Stage Kidney Disease market?

Top companies include Fresenius, DaVita, and Baxter, offering innovative dialysis products and services.

What are the future opportunities in the End-Stage Kidney Disease market?

Future opportunities include development of new dialysis technologies and increasing focus on emerging markets.

How will technology impact the End-Stage Kidney Disease market?

Technology will drive growth through advancements in dialysis machines, and remote patient monitoring systems.

What is the current regulatory landscape for the End-Stage Kidney Disease market?

The regulatory landscape is evolving, with a focus on patient safety, and strict guidelines for dialysis services.

What is the future outlook for the End-Stage Kidney Disease market?

The future outlook is positive, with increasing investment in research, and growing awareness about kidney disease.

End-Stage Kidney Disease Market Metrics & Forecast Analysis 2033

End-Stage Kidney Disease by Application (Hospital, Clinic, Others), by Types (Transplantation, Dialysis), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $13000 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $13000 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

End-Stage Kidney Disease Market Overview

The End-Stage Kidney Disease (ESKD) market refers to the industry focused on treating and managing the final stage of chronic kidney disease. As a critical area of healthcare, the End-Stage Kidney Disease market size is anticipated to reach approximately $24.6 billion by 2026. The growth outlook for this market is promising, with a market forecast indicating a compound annual growth rate (CAGR) of around 6.5% from 2026 to 2033, driven by factors such as an increasing prevalence of kidney diseases, an aging population, and advancements in dialysis technologies. The industry expansion is expected to be shaped by key forces including technology shifts towards home dialysis, regulatory support for innovative treatments, and changing consumer behaviors towards more personalized healthcare.

Loading chart…

The largest region in the ESKD market is currently North America, driven by high healthcare expenditure and a significant prevalence of kidney diseases. The fastest-growing region is anticipated to be Asia-Pacific, due to improving healthcare infrastructure and increasing awareness about kidney diseases. Key forces shaping the industry include technological advancements in dialysis equipment, regulatory frameworks supporting innovation, and consumer demand for more convenient and effective treatments. As the End-Stage Kidney Disease market continues to evolve, it is crucial for stakeholders to understand these dynamics to navigate the growth outlook and capitalize on emerging opportunities within the market forecast.

Report Overview

Report Attribute	Details
Market size value in 2025	13.00 billion
Revenue forecast in 2033	23.71 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Nipro Corporation; Fresenius Medical Care; Baxter International, Inc.; Medtronic Plc; B. Braun Melsungen AG; BD; Asahi Kasei Medical Co.,Ltd.; Cantel Medical; Nikkiso Co.,Ltd; JMS Co. Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The End-Stage Kidney Disease market is poised for significant growth, driven by increasing prevalence and advancements in treatment options. This section outlines the key dynamics influencing the End-Stage Kidney Disease market size and growth forecast.

Growth Drivers2 items

Advancements in dialysis technologies and services are expanding treatment options for patients with End-Stage Kidney Disease, contributing to the growth of the End-Stage Kidney Disease market

Government initiatives and reimbursement policies are improving access to care, further fueling the growth of the End-Stage Kidney Disease market size

Restraints2 items

High costs associated with End-Stage Kidney Disease treatment and management are limiting access to care, particularly in low-income countries, and hindering the growth forecast of the End-Stage Kidney Disease market

Stringent regulatory requirements and clinical trial protocols are slowing the development and approval of new treatments, affecting the End-Stage Kidney Disease market size

Opportunities2 items

Emerging technologies, such as artificial kidneys and kidney transplantation, are creating new opportunities for growth and innovation in the End-Stage Kidney Disease market

Increasing focus on preventive care and early intervention strategies is driving demand for End-Stage Kidney Disease treatments and services, contributing to the growth forecast

Challenges2 items

Managing the complexity of End-Stage Kidney Disease care and ensuring coordinated treatment approaches remain significant challenges in the End-Stage Kidney Disease market

Addressing health disparities and improving access to care for underserved populations are critical challenges that must be addressed to realize the full growth potential of the End-Stage Kidney Disease market size

Market Segmentation

Loading chart…

The End-Stage Kidney Disease segmentation is a crucial aspect of understanding the market dynamics. In terms of Application, the market can be segmented into various categories, including dialysis and kidney transplantation. Dialysis is further sub-segmented into hemodialysis and peritoneal dialysis, while kidney transplantation can be segmented into living donor transplantation and deceased donor transplantation. Each of these sub-segments contributes to the overall End-Stage Kidney Disease market size, with dialysis being the largest contributor due to the high prevalence of kidney disease and the limited number of available kidneys for transplantation.

The Types of End-Stage Kidney Disease can be segmented into various subtypes, including diabetic nephropathy, hypertensive nephrosclerosis, glomerulonephritis, and polycystic kidney disease. Diabetic nephropathy is the most common cause of End-Stage Kidney Disease, followed by hypertensive nephrosclerosis. Understanding these subtypes is essential for developing effective treatment strategies and for market taxonomy purposes. Each subtype has a different underlying pathology and requires a unique approach to management, making it essential to consider these differences when analyzing the End-Stage Kidney Disease market.

End-Stage Kidney Disease Segmentation Breakdown7 items

Application

Hospital

Clinic

Others

Types

Transplantation

Dialysis

Regional Insights

Loading chart…

The End-Stage Kidney Disease market growth is expected to vary across regions, with Asia Pacific being the largest region, accounting for approximately 35% of the global market. This region is also expected to be the fastest-growing, driven by increasing adoption of dialysis and kidney transplantation, government policies supporting healthcare infrastructure development, and investments in research and development.

In North America, key drivers include a high prevalence of diabetes and hypertension, a well-established healthcare infrastructure, and a favorable ecosystem maturity for innovative treatments. Europe is driven by an aging population, policies supporting organ donation, and a strong pharmaceutical industry. Latin America and Middle East & Africa are driven by increasing awareness of kidney disease, demographic changes, and infrastructure development.

The regional forecast indicates a growing demand for End-Stage Kidney Disease treatments, with the Asia Pacific region expected to drive market growth. Understanding the key drivers and trends in each region is crucial for stakeholders to navigate the End-Stage Kidney Disease market effectively.

Competitive Landscape

The End-Stage Kidney Disease market is moderately consolidated, driven by a mix of global players and local companies. The End-Stage Kidney Disease competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and strategic partnerships to maintain their market position, while local companies concentrate on regional expansion and cost advantages.

Companies in the End-Stage Kidney Disease market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies focus on technology, service model, channel strength, customization, and cost advantages. The following companies have notable strategic focuses:

Nipro Corporation: regional expansion

Fresenius Medical Care: vertical integration

Baxter International, Inc.: premium pricing

Medtronic Plc: innovation pipeline

B. Braun Melsungen AG: local manufacturing

BD: OEM tie-ups

Key End-Stage Kidney Disease Companies10 items

Nipro Corporation

Fresenius Medical Care

Baxter International, Inc.

Medtronic Plc

B. Braun Melsungen AG

Asahi Kasei Medical Co.,Ltd.

Cantel Medical

Nikkiso Co.,Ltd

JMS Co. Ltd.

Market Ecosystem

The End-Stage Kidney Disease ecosystem encompasses a complex network of stakeholders, from upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three stages: upstream, where raw materials and components are sourced; midstream, where these inputs are integrated into treatments and services; and downstream, where these offerings are delivered to end users through various channels. Value is created and captured throughout this ecosystem as technology providers, integrators, and channels work together to provide life-sustaining therapies to patients with End-Stage Kidney Disease.

Raw material/component suppliers — provide dialysis equipment and pharmaceuticals

OEMs / manufacturers — produce medical devices for dialysis

Technology providers — develop innovative therapies and digital health solutions

System integrators / EPCs — integrate dialysis systems and infrastructure

Distributors / channel partners — deliver medical products and services to healthcare providers

Service providers / after-sales — offer maintenance, training, and support for dialysis equipment

Regulators/standards bodies — establish and enforce safety and efficacy standards for treatments

In the End-Stage Kidney Disease ecosystem, control points are primarily held by regulators and standards bodies, as well as by large OEMs and technology providers that influence the adoption of new therapies and technologies. Dependency risks arise from input constraints, such as shortages of key components or pharmaceuticals, and from the need for regulatory approvals. Switching costs are high for end users, given the complexity and cost of dialysis equipment and the need for ongoing maintenance and support. The ecosystem differs by region, with varying levels of access to healthcare services and technologies in different parts of the world, requiring a nuanced approach to value chain analysis.

Recent Industry Insights

The End-Stage Kidney Disease industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and dialysis providers, have focused on improving patient outcomes and expanding access to care. Notable mergers and acquisitions have also taken place, with companies seeking to strengthen their presence in the market. Furthermore, innovative product launches, including wearable dialysis devices and advanced water treatment systems, have enhanced the quality of life for patients with End-Stage Kidney Disease. Regulatory changes, such as updates to reimbursement policies, have also impacted the industry, while shifts in consumer trends have led to increased demand for home-based dialysis solutions. Funding rounds and expansions have supported the growth of companies developing new therapies and technologies for the treatment of End-Stage Kidney Disease.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the End-Stage Kidney Disease market. The market attractiveness is moderate, driven by an increasing prevalence of kidney disease and a growing demand for effective treatments. The competitive intensity is high, with several major players competing for market share. Looking at the End-Stage Kidney Disease market outlook, the long-term prospects are promising, with advancements in dialysis and kidney transplantation expected to drive growth. The innovation landscape is evolving, with a focus on developing more efficient and cost-effective treatments. However, the demand–supply balance is a concern, with a shortage of available kidneys for transplantation. Key risk factors include regulatory changes, reimbursement pressures, and the high cost of treatments.

11 items

1. Executive Summary

2. End-Stage Kidney Disease Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global End-Stage Kidney Disease Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global End-Stage Kidney Disease Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Others

6.2. Global End-Stage Kidney Disease Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Transplantation

6.2.2. Dialysis

6.3. Global End-Stage Kidney Disease Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global End-Stage Kidney Disease Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global End-Stage Kidney Disease Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global End-Stage Kidney Disease Market Competition by Key Manufacturers

8.1. Global End-Stage Kidney Disease Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global End-Stage Kidney Disease: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Nipro Corporation

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Fresenius Medical Care

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Baxter International, Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Medtronic Plc

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. B. Braun Melsungen AG

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. BD

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Asahi Kasei Medical Co.,Ltd.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Cantel Medical

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Nikkiso Co.,Ltd

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. JMS Co. Ltd.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global End-Stage Kidney Disease Market

Figure 4: Global End-Stage Kidney Disease Market: Drivers

Figure 5: Global End-Stage Kidney Disease Market: Challenges

Figure 6: Global End-Stage Kidney Disease Market: Trends

Figure 7: Global End-Stage Kidney Disease Market: Opportunity

Figure 8: Global End-Stage Kidney Disease Market: Restraint

Figure 9: Global End-Stage Kidney Disease Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global End-Stage Kidney Disease Market Value (USD Million) By Region

Figure 15: Global End-Stage Kidney Disease Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global End-Stage Kidney Disease Market Value (USD Million) By Region

Figure 23: Global End-Stage Kidney Disease Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global End-Stage Kidney Disease Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global End-Stage Kidney Disease Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global End-Stage Kidney Disease Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global End-Stage Kidney Disease Market Value (USD Million) By Region

Table 10: Global End-Stage Kidney Disease Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global End-Stage Kidney Disease Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global End-Stage Kidney Disease Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global End-Stage Kidney Disease Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Nipro Corporation Basic Information And Sales Area

Table 31: Nipro Corporation. Products Portfolio

Table 32: Fresenius Medical Care Basic Information And Sales Area

Table 33: Fresenius Medical Care. Products Portfolio

Table 34: Baxter International, Inc. Basic Information And Sales Area

Table 35: Baxter International, Inc.. Products Portfolio

Table 36: Medtronic Plc Basic Information And Sales Area

Table 37: Medtronic Plc. Products Portfolio

Table 38: B. Braun Melsungen AG Basic Information And Sales Area

Table 39: B. Braun Melsungen AG. Products Portfolio

Table 40: BD Basic Information And Sales Area

Table 41: BD. Products Portfolio

Table 42: Asahi Kasei Medical Co.,Ltd. Basic Information And Sales Area

Table 43: Asahi Kasei Medical Co.,Ltd.. Products Portfolio

Table 44: Cantel Medical Basic Information And Sales Area

Table 45: Cantel Medical. Products Portfolio

Table 46: Nikkiso Co.,Ltd Basic Information And Sales Area

Table 47: Nikkiso Co.,Ltd. Products Portfolio

Table 48: JMS Co. Ltd. Basic Information And Sales Area

Table 49: JMS Co. Ltd.. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global End-Stage Kidney Disease Market Value (USD Million) By Region

Table 55: Global End-Stage Kidney Disease Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

End-Stage Kidney Disease Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	13.00 billion
Revenue forecast in 2033	23.71 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Nipro Corporation; Fresenius Medical Care; Baxter International, Inc.; Medtronic Plc; B. Braun Melsungen AG; BD; Asahi Kasei Medical Co.,Ltd.; Cantel Medical; Nikkiso Co.,Ltd; JMS Co. Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advancements in dialysis technologies and services are expanding treatment options for patients with End-Stage Kidney Disease, contributing to the growth of the End-Stage Kidney Disease market

Government initiatives and reimbursement policies are improving access to care, further fueling the growth of the End-Stage Kidney Disease market size

Restraints2 items

Stringent regulatory requirements and clinical trial protocols are slowing the development and approval of new treatments, affecting the End-Stage Kidney Disease market size

Opportunities2 items

Emerging technologies, such as artificial kidneys and kidney transplantation, are creating new opportunities for growth and innovation in the End-Stage Kidney Disease market

Increasing focus on preventive care and early intervention strategies is driving demand for End-Stage Kidney Disease treatments and services, contributing to the growth forecast

Challenges2 items

Managing the complexity of End-Stage Kidney Disease care and ensuring coordinated treatment approaches remain significant challenges in the End-Stage Kidney Disease market

Market Segmentation

Loading chart…

End-Stage Kidney Disease Segmentation Breakdown7 items

Application

Hospital

Clinic

Others

Types

Transplantation

Dialysis

Regional Insights

Loading chart…

Competitive Landscape

Nipro Corporation: regional expansion

Fresenius Medical Care: vertical integration

Baxter International, Inc.: premium pricing

Medtronic Plc: innovation pipeline

B. Braun Melsungen AG: local manufacturing

BD: OEM tie-ups

Key End-Stage Kidney Disease Companies10 items

Nipro Corporation

Fresenius Medical Care

Baxter International, Inc.

Medtronic Plc

B. Braun Melsungen AG

Asahi Kasei Medical Co.,Ltd.

Cantel Medical

Nikkiso Co.,Ltd

JMS Co. Ltd.

Market Ecosystem

Raw material/component suppliers — provide dialysis equipment and pharmaceuticals

OEMs / manufacturers — produce medical devices for dialysis

Technology providers — develop innovative therapies and digital health solutions

System integrators / EPCs — integrate dialysis systems and infrastructure

Distributors / channel partners — deliver medical products and services to healthcare providers

Service providers / after-sales — offer maintenance, training, and support for dialysis equipment

Regulators/standards bodies — establish and enforce safety and efficacy standards for treatments

Recent Industry Insights

Analyst Overview

Table of Contents